Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Operating Income: 2019-2024

Historic Operating Income for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$415.6 million.

  • Beam Therapeutics' Operating Income fell 19.07% to -$126.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$466.3 million, marking a year-over-year decrease of 155.26%. This contributed to the annual value of -$415.6 million for FY2024, which is 135.47% down from last year.
  • Beam Therapeutics' Operating Income amounted to -$415.6 million in FY2024, which was down 135.47% from -$176.5 million recorded in FY2023.
  • Beam Therapeutics' 5-year Operating Income high stood at -$132.8 million for FY2020, and its period low was -$415.6 million during FY2024.
  • Over the past 3 years, Beam Therapeutics' median Operating Income value was -$338.5 million (recorded in 2022), while the average stood at -$310.2 million.
  • In the last 5 years, Beam Therapeutics' Operating Income slumped by 195.62% in 2021 and then surged by 47.86% in 2023.
  • Beam Therapeutics' Operating Income (Yearly) stood at -$132.8 million in 2020, then tumbled by 195.62% to -$392.5 million in 2021, then climbed by 13.76% to -$338.5 million in 2022, then surged by 47.86% to -$176.5 million in 2023, then slumped by 135.47% to -$415.6 million in 2024.